Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 13

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part II, Item 2
Chunk 13
---
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a)    On October 21, 2024, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park. During the period from July 1, 2025 to September 30, 2025, we sold 900,000 shares of our common stock to Lincoln Park under that purchase agreement for aggregate gross proceeds of approximately $2.1 million. For additional information regarding our purchase agreement with Lincoln Park, see Note 4 “Stockholders’ Equity” to the accompanying condensed consolidated financial statements. Lincoln Park represented to us, among other things, that it is an “accredited investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”). The shares of common stock issued to Lincoln Park under the purchase agreement were issued in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.

(b)    None.

(c)    None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

(a)     None.

(b)     None.

(c)     During the period from July 1, 2025 to September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K) or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K). 

49

Item 6. Exhibits

Incorporated by ReferenceExhibitNumberDescription of ExhibitFormFile No.Filing DateExhibit No.Filed Herewith10.1Amendment No. 1 to Daré  Bioscience, Inc. 2022 Stock Incentive Plan10-Q001-363958/14/202510.110.2Grant Agreement between Daré Bioscience, Inc. and the Gates Foundation (f/k/a The Bill & Melinda Gates Foundation)  effective as of June 30, 202